Physician profile
Arjun Sood
NPI 1518092766
$5,261.91
in general payments reported to CMS, 2019-2025
55 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $101 · 2021: $302 · 2022: $971 · 2023: $1,156 · 2024: $1,042 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.51 |
| Education | $107.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $875.11 | 2020-2025 | Rybrevant, Darzalex, Erleada |
| Novartis Pharmaceuticals Corporation | $733.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $323.00 | 2019-2025 | Opdivo, Eliquis, Empliciti |
| Regeneron Healthcare Solutions, INC. | $194.08 | 2021-2025 | Libtayo |
| Daiichi Sankyo INC. | $179.92 | 2021-2025 | Enhertu, Datroway |
| Pfizer INC. | $174.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $157.76 | 2022-2025 | Keytruda, Keytruda Qlex |
| Celgene Corporation | $155.93 | 2019-2025 | Opdualag, Pomalyst, Reblozyl |
| Amgen INC. | $126.35 | 2019-2023 | Lumakras |
| Taiho Oncology, INC. | $126.34 | 2022-2024 | |
| Exelixis INC. | $125.71 | 2024-2025 | Cabometyx |
| Kite Pharma, INC. | $112.22 | 2021-2023 | Yescarta |
| Janssen Pharmaceuticals, INC | $106.76 | 2023-2025 | Xarelto |
| Pharmacyclics LLC, An Abbvie Company | $97.98 | 2019-2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $91.95 | 2023-2025 | Monoferric, Cosela |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.